Esther Colomier, Janita Halminen, Malin Björck, Gudrún Höskuldsdóttir, Karin Mossberg, My Engström, Björn Eliasson, Ville Wallenius, Lars Fändriks, Jan Tack, Hans Törnblom, Magnus Simrén
{"title":"Prevalence and Factors Associated With Symptom Profiles of Disorders of Gut-Brain Interaction in Obesity Before and After Treatment.","authors":"Esther Colomier, Janita Halminen, Malin Björck, Gudrún Höskuldsdóttir, Karin Mossberg, My Engström, Björn Eliasson, Ville Wallenius, Lars Fändriks, Jan Tack, Hans Törnblom, Magnus Simrén","doi":"10.1111/nmo.70017","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Disorders of gut-brain interaction (DGBI) in obesity could impair health outcomes. Therefore, we aimed to study the prevalence and burden of symptoms compatible with a DGBI in obesity and assess the effect of obesity treatment on comorbid DGBI.</p><p><strong>Methods: </strong>We used baseline and two-year follow-up data from a prospective non-randomized cohort study including patients with obesity referred for obesity treatment. Patients completed the Rome III questionnaire before and after receiving Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), or medical treatment. Validated questionnaires and blood parameters were used to assess the burden of DGBI in obesity.</p><p><strong>Results: </strong>In total, 939 patients (73% female, 44 ± 13 years, 42 ± 5 kg/m<sup>2</sup>, 36% medical treatment, 38% RYGB, 20% SG) completed the Rome III questionnaire at baseline and 651 patients (32 ± 6 kg/m<sup>2</sup>) at follow-up. The proportion of patients with a DGBI symptom profile was reduced from 61% (24% esophageal, 27% gastroduodenal, 38% bowel, and 8% anorectal disorders) to 53% (15% esophageal, 25% gastroduodenal, 34% bowel, 8% anorectal disorders) at follow-up. There was a substantial shift between the baseline and follow-up DGBI symptom profiles across all GI regions. Patients with a DGBI symptom profile at baseline presented with more severe psychological distress, a poorer quality of life, and were more likely to be female.</p><p><strong>Conclusions: </strong>DGBI symptom profiles are common and can impair health outcomes in obesity. Obesity treatment lowers the prevalence of DGBI symptoms in general, but an important shift between baseline and follow-up DGBI symptom profiles across all GI regions can be observed.</p>","PeriodicalId":19123,"journal":{"name":"Neurogastroenterology and Motility","volume":" ","pages":"e70017"},"PeriodicalIF":3.5000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurogastroenterology and Motility","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/nmo.70017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background & aims: Disorders of gut-brain interaction (DGBI) in obesity could impair health outcomes. Therefore, we aimed to study the prevalence and burden of symptoms compatible with a DGBI in obesity and assess the effect of obesity treatment on comorbid DGBI.
Methods: We used baseline and two-year follow-up data from a prospective non-randomized cohort study including patients with obesity referred for obesity treatment. Patients completed the Rome III questionnaire before and after receiving Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), or medical treatment. Validated questionnaires and blood parameters were used to assess the burden of DGBI in obesity.
Results: In total, 939 patients (73% female, 44 ± 13 years, 42 ± 5 kg/m2, 36% medical treatment, 38% RYGB, 20% SG) completed the Rome III questionnaire at baseline and 651 patients (32 ± 6 kg/m2) at follow-up. The proportion of patients with a DGBI symptom profile was reduced from 61% (24% esophageal, 27% gastroduodenal, 38% bowel, and 8% anorectal disorders) to 53% (15% esophageal, 25% gastroduodenal, 34% bowel, 8% anorectal disorders) at follow-up. There was a substantial shift between the baseline and follow-up DGBI symptom profiles across all GI regions. Patients with a DGBI symptom profile at baseline presented with more severe psychological distress, a poorer quality of life, and were more likely to be female.
Conclusions: DGBI symptom profiles are common and can impair health outcomes in obesity. Obesity treatment lowers the prevalence of DGBI symptoms in general, but an important shift between baseline and follow-up DGBI symptom profiles across all GI regions can be observed.
期刊介绍:
Neurogastroenterology & Motility (NMO) is the official Journal of the European Society of Neurogastroenterology & Motility (ESNM) and the American Neurogastroenterology and Motility Society (ANMS). It is edited by James Galligan, Albert Bredenoord, and Stephen Vanner. The editorial and peer review process is independent of the societies affiliated to the journal and publisher: Neither the ANMS, the ESNM or the Publisher have editorial decision-making power. Whenever these are relevant to the content being considered or published, the editors, journal management committee and editorial board declare their interests and affiliations.